

## OLPRUVA - (2000MG, 3000MG, 4000MG, 5000MG, 6000MG, 6670MG, 500MG, 1000MG Packet ; For Suspension)

<b>Generic Name</b>	SODIUM PHENYL BUTYRATE	<b>Innovator</b>	Acer
<b>Dosage</b>	2000MG, 3000MG, 4000MG, 5000MG, 6000MG, 6670MG, 500MG, 1000MG Packet ; For Suspension	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	OLPRUVA is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients weighing 20 kg or greater and with a body surface area (BSA) of 1.2 m <sup>2</sup> or greater, with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.